In Vivo Solutions for Radiopharmaceuticals
At Rdcthera, we specialize in providing integrated preclinical contract research services in the area of radiopharmaceuticals. We have an experienced in vivo team that delivers solutions in support of radiopharmaceutical development, evaluation, and optimization to the best possible standard of efficacy and safety.
In Vivo Studies in Radiopharmaceutical Research
In vivo studies play a vital role in radiopharmaceutical development. Studies like these provide very useful information on the behavior of radiopharmaceuticals in the living organism regarding their distribution, metabolism, efficacy, and safety. This information will yield successful translation of radiopharmaceuticals from bench to bedside.
Fig. 1. In vivo imaging and biodistribution study. (Yang C, et al., 2018)
Our Radiopharmaceutical In Vivo Solutions
At Rdcthera, we can provide you with a cutting-edge suite of in vivo study services tailored to support any stage in the development of radiopharmaceuticals. The service is tailored to provide critical insights and data for proving the safety and efficacy of radiopharmaceuticals.
Our in vivo models represent a wide array of animal species and diseases, enabling us to address diverse research needs. We employ small animals such as mice and rats for early stages of studies and larger models such as rabbits and non-human primates for more advanced evaluations.
We can offer our services in the development of animal models in the following aspects of diseases:
- Cancer
- Cardiovascular Disease
- Neurological Disease
- Metabolic Disease
Comprehensive In Vivo Research Services
Our biodistribution analysis service provides detailed information on the radiopharmaceutical distribution pattern within organs and tissues as a function of time. This information is therefore highly relevant to understanding targeting efficiency and possible off-target effects of these compounds and thus facilitates the optimization of dosage and delivery methods.
Read More
We employ the Medical Internal Radiation Dose (MIRD) principle for accurate dosimetry calculations. Our dosimetry services include pharmacokinetic modeling to derive time-activity curves, biodistribution data analysis, and small animal SPECT/PET quantitative imaging. We use voxel-based and small-scale dosimetry models to ensure precise radiation dose assessments.
Read More
Our efficacy evaluation services include rigorous testing that defines the therapeutic potential of radiopharmaceuticals. Providing relevant disease models, we assess the compound's ability to achieve the desired therapeutic effect, thus providing critical data to support further development and regulatory submissions.
Read More
Our in vivo PK studies deliver detailed information on the ADME of radiopharmaceuticals. Such research is conducted in order to understand very clearly the PK profile of the compound, guide dose selection, and optimize therapeutic regimens.
Read More
Safety pharmacology is one of the prime elements in the course of development of new radiopharmaceuticals. Our in vivo safety pharmacology studies are aimed at examining possible adverse effects of radiopharmaceuticals on vital organ systems, such as the cardiovascular, central nervous, and respiratory systems, using state-of-the-art methodologies and models in animals.
Read More
We conduct single-dose and repeated-dose toxicity studies in order to identify the possible toxic effects of radiopharmaceuticals. Full-range evaluations include hematology, clinical chemistry, necropsy data, histopathology, pharmacokinetics, and dose determination to guarantee the thorough safety profiling of a compound.
Read More
Our state-of-the-art in vivo imaging services utilize leading-edge technologies: PET, SPECT, CT, and MRI, to visualize and quantify radiopharmaceutical distribution and activity in living organisms. Noninvasive techniques allow real-time data acquisition and enhance one's understanding of the pharmacokinetics and biodistribution of molecules under study.
Read More
Why Choose Rdcthera?
- Expertise in Radiopharmaceuticals
- Advanced In Vivo Models
- Cutting-Edge Technology
- Comprehensive Services
- Customized Solutions
- Commitment to Quality
Ready to advance your radiopharmaceutical research? Contact us today to learn more about our in vivo solutions and how we can support your projects. At Rdcthera, we are committed to helping you achieve your research goals with precision and excellence.
Reference
- Yang C, Wu T, Qin Y, et al. (2018). A facile doxorubicin-dichloroacetate conjugate nanomedicine with high drug loading for safe drug delivery. Int J Nanomedicine. 13:1281-1293.
For research use only. Not intended for any clinical use.
Related Service
